Nicox Secures April 2027 PDUFA Date for NCX 470 Glaucoma Drug NDA

With an NDA acceptance letter in hand and a 30 April 2027 PDUFA date confirmed, Nicox and its U.S. licensee Kowa now face a defined regulatory clock for NCX 470 (bimatoprost grenod), a nitric oxide-donating prostaglandin analog targeting open-angle glaucoma and ocular hypertension. For CMC leads and regulatory affairs teams, FDA acceptance signals that the dossier clears the threshold of completeness for formal review under 21 CFR Part 314, but the substantive work on analytical characterisation of the NO-donating moiety begins now.

NCX 470 combines bimatoprost and a nitric oxide-releasing component in a single molecule, lowering intraocular pressure through two distinct mechanisms: prostaglandin analog-mediated uveoscleral outflow and NO-driven trabecular drainage via soluble guanylate cyclase activation. That dual-mechanism architecture places the compound in a novel formulation class, with CMC documentation requirements that extend beyond standard ophthalmic small-molecule precedents. Sponsors working on similar NO-hybrid platforms should monitor the agency's review correspondence closely for any chemistry or stability-related information requests.

The NDA was submitted by Kowa on 30 June 2026, supported by efficacy and safety data from the Mont Blanc and Denali Phase 3 trials, both of which met primary endpoints and demonstrated IOP reductions of up to 10 mmHg. A parallel NDA filed in China, with Ocumension Therapeutics as commercial partner, was submitted in August 2026, extending the multi-market regulatory programme. A Phase 3 programme in Japan remains ongoing.

Commercial infrastructure is already positioned: both Kowa in the U.S. and Ocumension in China have established sales organisations, with launches targeted from H2 2027 subject to approval. NDA approval in the U.S. triggers a milestone payment to Nicox, followed by royalties on net sales, a structure that aligns partner incentives tightly with the regulatory outcome.

The 30 April 2027 PDUFA date gives QA and regulatory teams at Kowa approximately eight months to complete pre-approval inspection readiness, resolve any outstanding CMC queries, and align labelling strategy across the two major-market submissions.

Source: Nicox SA via GlobeNewswire, 27 August 2026.